Harrow, Inc. Selling and Marketing Expense
Harrow, Inc. (HROW) reported Selling and Marketing Expense of $7.06 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2018-03-08
- Harrow, Inc. selling and marketing expense for the quarter ending 2017-12-31 was $1.33M, a 5.87% decline year-over-year.
- Harrow, Inc. selling and marketing expense for the quarter ending 2017-09-30 was $1.29M, a 28.32% decline year-over-year.
- Harrow, Inc. selling and marketing expense for the quarter ending 2017-06-30 was $2.00M, a 11.94% decline year-over-year.
- Harrow, Inc. selling and marketing expense for the quarter ending 2017-03-31 was $2.44M, a 28.42% increase year-over-year.
- Harrow, Inc. selling and marketing expense for fiscal 2017 was $7.06M, a 4.38% decline from fiscal 2016.
- Harrow, Inc. selling and marketing expense for fiscal 2016 was $7.38M, a 13.64% increase from fiscal 2015.
- Harrow, Inc. selling and marketing expense for fiscal 2015 was $6.50M, a 171.80% increase from fiscal 2014.
- Harrow, Inc. selling and marketing expense for fiscal 2014 was $2.39M, a 2682.63% increase from fiscal 2013.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $2.62M derived: sum of 2 quarters · filed 2018-03-08 | $4.62M derived: sum of 3 quarters · filed 2018-03-08 | $7.06M 10-K · filed 2018-03-08 | ||||
| 2017-09-30 | $1.29M 10-Q · filed 2017-11-14 | $3.29M derived: sum of 2 quarters · filed 2017-11-14 | $5.73M 10-Q · filed 2017-11-14 | $7.14M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2017-06-30 | $2.00M 10-Q · filed 2017-08-10 | $4.44M 10-Q · filed 2017-08-10 | $5.85M derived: sum of 3 quarters · filed 2018-03-08 | $7.65M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2017-03-31 | $2.44M 10-Q · filed 2017-05-10 | $3.85M derived: sum of 2 quarters · filed 2018-03-08 | $5.65M derived: sum of 3 quarters · filed 2018-03-08 | $7.92M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $3.21M derived: sum of 2 quarters · filed 2018-03-08 | $5.48M derived: sum of 3 quarters · filed 2018-03-08 | $7.38M 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | $1.80M 10-Q · filed 2017-11-14 | $4.07M derived: sum of 2 quarters · filed 2017-11-14 | $5.97M 10-Q · filed 2017-11-14 | $8.01M derived: sum of 4 quarters · filed 2017-11-14 | ||||
| 2016-06-30 | $2.27M 10-Q · filed 2017-08-10 | $4.17M 10-Q · filed 2017-08-10 | $6.21M derived: sum of 3 quarters · filed 2017-08-10 | $8.02M derived: sum of 4 quarters · filed 2017-08-10 | ||||
| 2016-03-31 | $1.90M 10-Q · filed 2017-05-10 | $3.94M derived: sum of 2 quarters · filed 2017-05-10 | $5.75M derived: sum of 3 quarters · filed 2017-05-10 | $7.38M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $3.85M derived: sum of 2 quarters · filed 2017-03-21 | $5.48M derived: sum of 3 quarters · filed 2017-03-21 | $6.50M 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | $1.81M 10-Q · filed 2016-11-14 | $3.44M derived: sum of 2 quarters · filed 2016-11-14 | $4.46M 10-Q · filed 2016-11-14 | $5.38M derived: sum of 4 quarters · filed 2016-11-14 | ||||
| 2015-06-30 | $1.63M 10-Q · filed 2016-08-15 | $2.64M 10-Q · filed 2016-08-15 | $3.57M derived: sum of 3 quarters · filed 2016-08-15 | $4.21M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | $1.01M 10-Q · filed 2016-05-12 | $1.94M derived: sum of 2 quarters · filed 2016-05-12 | $2.58M derived: sum of 3 quarters · filed 2016-05-12 | $3.05M derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | $928.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $1.56M derived: sum of 2 quarters · filed 2016-03-23 | $2.03M derived: sum of 3 quarters · filed 2016-03-23 | $2.39M 10-K · filed 2016-03-23 | $2.39M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | $637.00K 10-Q · filed 2015-11-12 | $636.55K 10-Q · filed 2014-11-12 | $1.11M derived: sum of 2 quarters · filed 2015-11-12 | $1.46M 10-Q · filed 2015-11-12 | $1.46M 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $469.00K 10-Q · filed 2015-08-12 | $469.19K 10-Q · filed 2014-08-13 | $826.00K 10-Q · filed 2015-08-12 | $825.90K 10-Q · filed 2014-08-13 | ||||
| 2014-03-31 | $382.00K 10-Q · filed 2015-05-13 | |||||||
| 2013-12-31 | $85.89K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |